Navigation Links
OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
Date:5/14/2009

ival benefit of OGX-011, anticipated clinical development activities, timing of these activities, the ability of future trials to demonstrate clinical benefit and the potential for regulatory approvals. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements.

The potential risks and uncertainties associated with forward-looking statements include, among others, the possibility that any benefit in patient survival will not be maintained or will become less substantial as patient survival follow up continues, risks that clinical trials will not be successful or confirm earlier clinical trial results, including the risk that the survival benefit will not be confirmed by a Phase 3 clinical trial, risks associated with obtaining funding from third parties or completing a financing necessary to support the costs and expenses of a Phase 3 clinical trial, the timing and costs of clinical trials and regulatory approvals will be different than management currently anticipates, risks relating to the development, safety and efficacy of therapeutic drugs and potential applications for these products and the risk factors set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for fiscal year 2008. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
2. OncoGenex Reports First Quarter Financial Results
3. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
4. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
5. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
6. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
7. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
8. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
9. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
10. OncoGenex Reports Third Quarter Financial Results
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Switzerland (PRWEB) January 22, 2015 Selexis ... characterized mammalian Research Cell Banks (RCBs) used for drug ... Research Cell Banks will include Next-Generation Sequencing ... genetic architecture de-risks biologic manufacturing by ensuring the integrity ...
(Date:1/22/2015)... Nueva Jersey , 22 de enero de 2015  El ... abre hoy su llamada a nominaciones para 2015. Este ... ha hecho, o tiene el potencial para hacer, contribuciones ... nominaciones se aceptarán hasta el 15 de marzo de ...
(Date:1/22/2015)... , Jan. 22. 2015  Varian Medical Systems (NYSE: ... has been honored for its commitment to sustainability with inclusion ... Varian is the highest ranked healthcare equipment company among the ... during the World Economic Forum at Davos, Switzerland ...
(Date:1/22/2015)... PRINCETON, N.J. , Jan. 22, 2015  Derma ... tissue regeneration company focused on advanced wound care, ... from placental tissues, have been added to the ... announcement increases the opportunity for the AMNIOEXCEL® and ...
Breaking Biology Technology:Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Varian Honored Among World's 100 Most Sustainable Corporations 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5
... (NYSE: APD ) and Alter NRG Corp. ... Development Agreement (JDA) to pursue renewable energy opportunities in ... Air Products the right to license and incorporate Alter ... renewable energy projects. Air Products will initially focus ...
... SAN CLEMENTE, Calif., Feb. 4 To say that ... a series of successes in 2008 that are providing ... quite be telling the whole story. This past ... the young company, as it literally expanded its presence ...
... Board: GOVX), an Atlanta-based, publicly traded,biopharmaceutical company developing human ... other infectious agents, today,announced that its Corporate Presentation at ... live by Thomson Reuters. The Conference will be held ... 9 and 10, 2009. , ...
Cached Biology Technology:Air Products and Alter NRG Sign JDA on Renewable Energy Projects 2Air Products and Alter NRG Sign JDA on Renewable Energy Projects 3Air Products and Alter NRG Sign JDA on Renewable Energy Projects 4While Most Companies and Industries Struggled in 2008, LifeModeler, Inc. Used Unique Products to Post Aggressive Business Gains in All Areas 2While Most Companies and Industries Struggled in 2008, LifeModeler, Inc. Used Unique Products to Post Aggressive Business Gains in All Areas 3While Most Companies and Industries Struggled in 2008, LifeModeler, Inc. Used Unique Products to Post Aggressive Business Gains in All Areas 4GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference 2GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference 3
(Date:1/22/2015)... , Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading ... the launch of its new website design. "When ... its infancy", says Peter O,Neill , founder and CEO ... the industry needs involvement from the key players on a ...
(Date:1/22/2015)... Showcase, Hall E -   EyeLock Inc. , a market ... showcase its EyeLock ID technology integrated in a 3D printed ... Oak Ridge National Laboratory (ORNL) at the 2015 ... technology is being used to validate the driver and authorize ...
(Date:1/22/2015)... man-made form of insulin delivered by nasal spray may ... with mild cognitive impairment and Alzheimer,s disease dementia, according ... Forest Baptist Medical Center. The study,s subjects ... (MCI) or mild to moderate Alzheimer,s dementia (AD). Those ...
Breaking Biology News(10 mins):Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3
... A new systematic assessment of malnutrition, created by ... health care providers in diagnosis and treatment. Up ... facilities are estimated to be malnourished, according to Gordon ... Although malnutrition is widespread, confusion exists in the clinical ...
... discovered an Achilles heel within our cells that bacteria are ... The researchers say their findings could lead to the development ... has led to resistance. University of Manchester researchers studied ... that can cause listeriosis in humans when digested and ...
... Samuel M. Young, Jr., PhD, research group leader ... received his first grant from The Michael J. Fox ... enable Dr. Young and colleagues to develop a technology ... research potential treatments that target LRRK2, a Parkinson,s-related gene. ...
Cached Biology News:Researchers unveil new assessment for diagnosing malnutrition 2Michael J. Fox Foundation grant to Dr. Samuel Young will provide Parkinson's drug development tools 2Michael J. Fox Foundation grant to Dr. Samuel Young will provide Parkinson's drug development tools 3
... siSolutions siRNA Custom Synthesis ... effective duplex RNA to knockdown ... 21-mers (19 RNA base pairs ... recently-published 27-mers, or other lengths ...
Alexa Fluor 647 anti-mouse Qa-2...
...
Alexa Fluor 647 anti-mouse Qa-2...
Biology Products: